VANCOUVER, British Columbia, February 7, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: Human Genome Sciences (NASDAQ:HGSI), DryShips (NASDAQ:DRYS), Alcoa (NYSE:AA), and Threshold Pharmaceuticals (NASDAQ:THLD).
(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)
Report Highlights:
Human Genome Sciences (NASDAQ:HGSI): By the end of yesterday's trading, Human Genome Sciences (NASDAQ:HGSI) jumped as much as 6% to US$10.77. In the past 52 weeks, Human Genome Sciences share prices have been bracketed by a low of US$6.51 and a high of US$30.15, and are now at US$10.77, 65% above that low price. Are insiders starting to take huge profits by selling shares or exercising stock options? Add HGSI into your watch list for insider trade now.
Read Full Report: http://www.Pennystocksinsiders.com/PR/020712A/HGSI/HumanGenome.pdf
DryShips Inc. (NASDAQ:DRYS): DryShips Inc. (NASDAQ:DRYS) yesterday soared 16.63% higher, moving up US$0.40 to US$2.81 per share. Abnormal trading volume of DryShips Inc. was found which reached 27.79 million shares, 5.7 times heavier than usual day trading. Investors may want to find out how company insiders like Executive Officers and Directors are thinking about the future business prospects of the company. Check this insider trade report for DRYS here.
Read Full Report: http://www.Pennystocksinsiders.com/PR/020712A/DRYS/DryShips.pdf
Alcoa Inc. (NYSE:AA): Alcoa Inc. (NYSE:AA) lately introduced that Paula Davis was appointed as a Vice President. By the end of yesterday's trading, Alcoa Inc. dropped US$0.03 per share (equivalent to 0.23%), where stock prices fell to US$10.73. Pennystocksinsiders.com thinks that it is a clever way to check if insiders like CEOs, CFOs, and Directors in AA are starting to buy more company shares. See insider trade report for AA here.
Read Full Report: http://www.Pennystocksinsiders.com/PR/020712A/AA/Alcoa.pdf
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD): Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) and Merck KGaA recently have achieved a legal contract to co-develop and commercialize hypoxia-targeted drug TH-302. Threshold Pharmaceuticals, Inc. reached US$3.38, with 13.04% up. Abnormal trading volume of Threshold Pharmaceuticals was found on February 6 which reached 19.73 million shares, 32 times heavier than usual day trading. The company has a market cap of 166.05 million. Investors can reduce investment risk by checking insider trades in THLD. See if CEOs, CFOs, and Directors in THLD are trading the stock now.
Read Full Report: http://www.Pennystocksinsiders.com/PR/020712A/THLD/Threshold.pdf
About Pennystocksinsiders.com:
Pennystocksinsiders.com features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.
Important Disclaimer:
Please visit http://www.Pennystocksinsiders.com/disclaimers/index.php for details.
